How should hypertension be evaluated and managed in a 14-year-old boy?

Hypertension in 14-Year-Old Boys: Evaluation and Management

For a 14-year-old boy with hypertension, use the adult cutoff of ≥130/80 mm Hg to define hypertension, confirm the diagnosis with ambulatory blood pressure monitoring (ABPM), and initiate treatment with lifestyle modifications first, adding pharmacologic therapy (ACE inhibitor, ARB, long-acting calcium channel blocker, or thiazide diuretic) if BP remains elevated after 6-12 months or if there is evidence of target organ damage, symptomatic hypertension, or stage 2 hypertension. 1, 2

Diagnostic Criteria for a 14-Year-Old

Since this patient is ≥13 years old, the 2017 AAP guidelines simplified the diagnostic approach by aligning with adult definitions 1:

• Normal BP: <120/<80 mm Hg
• Elevated BP: 120-129/<80 mm Hg
• Stage 1 Hypertension: 130-139/80-89 mm Hg
• Stage 2 Hypertension: ≥140/90 mm Hg

This represents a significant departure from the percentile-based approach used in younger children and makes screening more straightforward.

Confirmation of Diagnosis

Do not diagnose hypertension based on a single office reading. The diagnosis requires elevated BP at 3 separate office visits unless the patient is symptomatic 1. However, ABPM is strongly recommended to confirm the diagnosis before initiating extensive workup or treatment 1. This is critical because:

• White-coat hypertension is highly prevalent in children and adolescents
• ABPM is cost-effective by preventing unnecessary testing and treatment in those with white-coat hypertension
• ABPM can identify masked hypertension (normal office BP but elevated ambulatory BP)

Use auscultatory BP measurement as the gold standard for office readings, not oscillometric devices 1.

Evaluation for Secondary Causes and Risk Factors

History and Physical Examination Focus

Look specifically for 2:

• Obesity (most common risk factor for primary hypertension)
• Family history of early-onset hypertension or cardiovascular disease
• Sleep symptoms suggesting obstructive sleep apnea (snoring, daytime sleepiness, witnessed apneas)
• Medication/substance use (stimulants, NSAIDs, oral contraceptives, anabolic steroids, illicit drugs)
• Symptoms of secondary causes: headaches, visual changes, chest pain, palpitations, muscle weakness, polyuria/polydipsia
• Physical findings: abdominal bruit (renovascular disease), delayed femoral pulses (coarctation), cushingoid features, thyroid enlargement

Laboratory and Imaging Workup

Initial laboratory studies 2:

• Complete metabolic panel (electrolytes, BUN, creatinine)
• Lipid panel
• Fasting glucose or HbA1c
• Urinalysis
• Complete blood count

Echocardiography is indicated to assess for left ventricular hypertrophy (LVH), which is the most common target organ damage in pediatric hypertension 1, 2. LVH is defined as LV mass >51 g/m^2.7 for adolescents >8 years old 2.

Consider renovascular imaging (Doppler renal ultrasound, CTA, or MRA) if 2:

• Stage 2 hypertension
• Significant diastolic hypertension
• Discrepant kidney sizes on ultrasound
• Abdominal bruit on examination
• Hypokalemia

Treatment Approach

Lifestyle Modifications (First-Line for All Patients)

Initiate immediately at diagnosis 2:

• DASH diet (Dietary Approaches to Stop Hypertension)
• Weight loss if overweight/obese through intensive weight-loss programs
• Physical activity: Moderate to vigorous exercise 3-5 days per week, 30-60 minutes per session
• Sodium restriction
• Avoid tobacco and excessive caffeine

Pharmacologic Therapy Indications

Start antihypertensive medication if 2:

1. Stage 2 hypertension without a clearly modifiable factor (e.g., not simply obesity-related)
2. Symptomatic hypertension (headaches, visual changes, chest pain)
3. Left ventricular hypertrophy on echocardiography
4. Persistent stage 1 hypertension after 6-12 months of lifestyle modifications
5. Secondary hypertension (treat the underlying cause and BP simultaneously)
6. Chronic kidney disease or diabetes with any level of hypertension

First-Line Antihypertensive Medications

Choose from these four classes 2:

1. ACE inhibitors (e.g., lisinopril, enalapril)
2. Angiotensin receptor blockers (ARBs) (e.g., losartan, olmesartan)
3. Long-acting calcium channel blockers (e.g., amlodipine)
4. Thiazide diuretics (e.g., hydrochlorothiazide, chlorthalidone)

All four classes are effective, safe, and well-tolerated in adolescents 3. If the patient has proteinuria or chronic kidney disease, prefer ACE inhibitors or ARBs 2.

Treatment Goal

Target BP <130/80 mm Hg (or <90th percentile for younger children) 2.

Follow-Up Strategy

If on Pharmacologic Therapy

• Every 4-6 weeks until BP is controlled, adjusting doses or adding agents as needed
• Once controlled, extend to every 3-4 months 2
• Monitor for medication adherence and adverse effects at each visit
• Consider repeat ABPM to assess treatment effectiveness 2

If on Lifestyle Modifications Only

• Every 3-6 months to reinforce adherence and reassess need for medication 2

Monitoring for Target Organ Damage

• Repeat echocardiography at 6-12 month intervals if LVH is present or if hypertension persists despite treatment 2
• For patients without initial LVH but with stage 2 hypertension or inadequately controlled stage 1 hypertension, consider yearly echocardiography 2

Critical Pitfalls to Avoid

1. Do not diagnose hypertension from a single elevated reading – requires confirmation at multiple visits or by ABPM
2. Do not skip ABPM – it prevents overdiagnosis of white-coat hypertension and identifies masked hypertension
3. Do not use oscillometric readings alone for diagnosis – confirm with auscultatory measurement
4. Do not delay pharmacologic treatment if there is LVH, symptomatic hypertension, or stage 2 hypertension
5. Do not forget to screen for comorbidities – diabetes, dyslipidemia, and obesity commonly coexist
6. Do not use home BP monitoring for diagnosis – insufficient evidence in pediatrics; use ABPM instead 1

Special Considerations

Sports participation: Adolescents with hypertension may participate in competitive sports once target organ effects and cardiovascular risk have been assessed, but BP should be reduced below stage 2 thresholds before participation 2.

Transition to adult care: Begin planning transition to an adult provider by age 22 to ensure continuity of care and long-term adherence 2.